BoomRx Launches Oral Testosterone Therapy to Expand TRT Access Beyond Clinics
Event summary
- BoomRx introduced an oral liquid testosterone replacement therapy (TRT) on February 11, 2026, designed for telemedicine and wellness providers.
- The nanoemulsion liquid formulation eliminates the need for injections, supporting telemedicine, med spas, and hybrid practice models.
- BoomRx aims to simplify TRT service expansion by removing the operational burden of in-office administration and inventory management.
- The product is available to qualified healthcare providers through the BoomRx platform.
The big picture
BoomRx's oral TRT launch targets the growing demand for scalable, telemedicine-friendly hormone replacement therapies. As men's health and wellness programs expand, the shift from injectable to oral formulations could lower operational barriers for providers. The move aligns with broader industry trends toward decentralized, patient-centric care models.
What we're watching
- Market Adoption
- How quickly telemedicine and wellness providers integrate the oral TRT into their service offerings.
- Regulatory Compliance
- Whether the nanoemulsion delivery method faces any regulatory scrutiny or approval hurdles.
- Competitive Response
- The pace at which competitors develop similar oral TRT solutions to capture market share.
Related topics